小细胞肺癌治疗中的抗血管生成药物研究进展  

Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer

作　　者：王晶 李凯 Wang Jing;Li Kai(Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin′s Clinical Research Center for Cancer,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院肺部肿瘤内科国家肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心,300060

出　　处：《中华肿瘤杂志》2020年第8期624-628,共5页Chinese Journal of Oncology

摘　　要：小细胞肺癌(SCLC)属于恶性程度高的神经内分泌肿瘤,侵袭性强,可迅速进展,是肺癌的一种特殊类型。SCLC对放疗和化疗敏感,多年来,放化疗一直是SCLC的主要一线治疗手段,但治疗后极易耐药,因此抗血管生成治疗的研究受到关注。目前,抗血管生成药物主要聚焦于单克隆抗体(如贝伐单抗)、内源性血管生成抑制剂(如恩度)、抗血管生成融合蛋白(如阿柏西普)和小分子酪氨酸激酶抑制剂(如安罗替尼等)4类。但抗血管生成药物的研究和临床应用还存在一些瓶颈,探索更好的联合治疗方案和有效的双领域、多靶点药物是努力的正确方向。Small cell lung cancer(SCLC),a special type of lung cancer,is a highly malignant neuroendocrine tumor with strong invasiveness and rapid progression.SCLC is sensitive to radiotherapy and chemotherapy,so radiotherapy and chemotherapy have been the main first-line treatment of SCLC.However,it is easy to develop drug resistance after treatment.Therefore,the study of anti-angiogenic therapy has attracted more and more attention.At present,anti-angiogenic drugs mainly focus on four categories:monoclonal antibodies(such as bevacizumab),endogenous angiogenesis inhibitors(such as endostar),anti-angiogenic fusion protein(such as aflibercept)and small molecular tyrosine kinase inhibitors(such as anlotinib).There are still some bottlenecks in the research and clinical application of antiangiogenic drugs.It is the right direction to explore better combination therapy and effective dual-field and multi-target drugs.

关 键 词：小细胞肺癌 抗血管生成药物 抗VEGF单克隆抗体 内源性血管生成抑制剂 小分子酪氨酸激酶抑制剂 进展 

分 类 号：R734.2[医药卫生—肿瘤]